SKYENew company, new playlist
Skye Bioscience and Redx Pharma just hit the corporate version of a plot twist: they’ve signed a definitive transaction agreement to create a combined company that will trade on Nasdaq as Fibrx Therapeutics. The setup puts the Redx management team and board in charge, while Skye’s shareholders are getting folded into a fibrosis-focused story.
Why investors should care
This isn’t just a branding exercise with a shinier logo. The combined company’s lead program will be RXC008, Redx’s GI-restricted pan-ROCK inhibitor aimed at fibrostenotic Crohn’s disease. That asset already has an open U.S. IND, FDA Fast Track designation, and a planned Phase 2 study, which is biotech-speak for: the science train is leaving the station, but the ride is still long.
The money part
The deal also comes with about $125 million in concurrent financings from a syndicate of new and existing healthcare investors. Translation: the company has enough fuel to keep the lights on and fund operations through the Phase 2 readout, with topline data now expected in H2 2028.
Big picture
For Skye holders, this is a classic biotech makeover: one public shell, one lead asset, a pile of financing, and a very patient timeline. If RXC008 works, today’s transaction could look smart in hindsight. If not, well, 2028 is a long time to wait for a verdict.